Introduction: The global incidence of diabetes mellitus is rising rapidly, and it is a major public health challenge now. In 2019, over 463 million people were affected worldwide, and this number is projected to increase to 700 million by 2045. Diabetes causes serious consequences, such as retinopathy, nephropathy, and cardiovascular illnesses. Conventional management strategies, including insulin therapy, oral hypoglycemic agents, and lifestyle modifications, often fail to achieve optimal glycaemic control. Recent advances in diabetes management have introduced novel therapeutic approaches such as immunotherapies, innovative pharmacological agents, and nanotechnology-based drug delivery systems. These emerging therapies aim to improve glycaemic control, enhance patient adherence, and reduce the risk of diabetes-related complications.

Aim and Objectives: To explore the new treatment options or advancement of Diabetes Mellitus.

Material and Methods: Various studies from Embase, PubMed, and the Web of Science were searched until Dec, 2025. Systematic review, meta-analysis, peer-reviewed papers, and conference abstracts were analysed. Recent developments in diabetes treatment are novel therapeutic approaches, including immunological therapies, novel pharmacological agents, and nanotechnology-based drug delivery systems. The goals of these new therapies are to reduce the risk of complications, enhance patient compliance, and improve glycemic management.

Results: Innovative Agents Under Development- These include Amylin/GLP-1 dual receptor agonists, GIP/glucagon/GLP-1 triple receptor agonists, Non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist, Once-weekly basal insulin analog, Emerging Treatment Techniques - Treatment with Oral Hypoglycemics Using Nanocarriers, Liposomes, Niosomes, Micelles, Nanoemulsion, Polymeric Nanoparticles, Solid Lipid Nanoparticles, Carbon Nanotubes. Immunological Approach- Cyclosporin A (CsA), Rituximab, Anti-TNF-α, GAD-65 (Glutamic Acid Decarboxylase 65) , Insulin Secretagogues (TAK-875)

Conclusion: The integration of novel therapies, including immunological treatments and nanotechnology-based drug delivery systems, offers promising advances in diabetes management. These approaches aim to improve glycaemic control, reduce complications, and enhance quality of life. Continued research is essential to develop more effective and personalized diabetes therapies.

Nalini Kumari is a medical doctor, researcher, author, and writer. Currently working in drug development for various regulatory submission US FDA, EU, HEALTH CANADA, RUSSIA, CHINA, GCC, having hands-on experience in phase 1 clinical trials in human beings, deep knowledge of pharmacotherapeutics, regulatory guidelines, and ICH GCP guidelines